This trial will test whether CC-90011 can make tumors sensitive to anti-hormonal therapy again by inducing androgen receptor expression.
1 Primary · 3 Secondary · Reporting Duration: Through study completion, Up to 1.5 years
1 Treatment Group
CC-90011 in combination with Abiraterone and Prednisone
1 of 1
10 Total Participants · 1 Treatment Group
Primary Treatment: CC-90011 · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · Male Participants · 8 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Has CC-90011 been the focus of prior scientific exploration?
"Presently, there are 366 ongoing trials involving CC-90011 with a hundred of those in the final phase. While most experiments concerning this drug are based out of Duarte, California, over 17 thousand sites worldwide have started research into this medication." - Anonymous Online Contributor
What is the cutoff for participants being allowed to join this research endeavor?
"Affirmative. According to clinicaltrials.gov, this medical research is still in the recruitment process. It was initially posted on July 28th 2021 and recently updated on July 21st 2022. The study requires 10 patients from a single site." - Anonymous Online Contributor
To what medical conditions is CC-90011 typically prescribed?
"CC-90011 is a therapeutic agent used to treat thyroiditis and other maladies including ulcerative colitis, cancerous growths, and varicella-zoster virus acute retinal necrosis." - Anonymous Online Contributor
To what extent do the risks of CC-90011 outweigh its potential advantages?
"CC-90011 is a relatively new medication, so its safety score was assessed at 1. This reflects the fact that there are only limited clinical data supporting both efficacy and safety in this Phase 1 trial." - Anonymous Online Contributor
Is there any vacancy for participants in this trial?
"According to the clinicaltrials.gov records, this study has been recruiting since its inception on July 28th 2021 and is still actively enrolling patients as of the latest update dated July 21st 2022." - Anonymous Online Contributor